Results 1 to 10 of about 458,797 (215)

Editorial: Cancer systems biology [PDF]

Frontiers in Genetics, 2022
Jesús Espinal-Enríquez, Claudia Rangel-Escareño, Claudia Rangel-Escareño, Frank Emmert-Streib   +3 more
doaj   +2 more sources

A census of pathway maps in cancer systems biology. [PDF]

Nat Rev Cancer, 2020
Kuenzi BM, Ideker T.
europepmc   +2 more sources

Cancer Systems Biology: a peek into the future of patient care? [PDF]

Nat Rev Clin Oncol, 2014
Werner HM, Mills GB, Ram PT.
europepmc   +2 more sources

A persistent invasive phenotype in post-hypoxic tumor cells is revealed by fate mapping and computational modeling

iScience, 2021
Summary: Hypoxia is a critical factor in solid tumors that has been associated with cancer progression and aggressiveness. We recently developed a hypoxia fate mapping system to trace post-hypoxic cells within a tumor for the first time.
Heber L. Rocha, Inês Godet, Furkan Kurtoglu, John Metzcar, Kali Konstantinopoulos, Soumitra Bhoyar, Daniele M. Gilkes, Paul Macklin   +7 more
doaj   +1 more source

A network approach reveals driver genes associated with survival of patients with triple-negative breast cancer

iScience, 2021
Summary: We aimed to identify triple-negative breast cancer (TNBC) drivers that regulate survival time as predictive signatures that improve TNBC prognostication.
Courtney D. Dill, Eric B. Dammer, Ti'ara L. Griffen, Nicholas T. Seyfried, James W. Lillard, Jr.   +4 more
doaj   +1 more source

Tumor microenvironment mimicking 3D models unveil the multifaceted effects of SMAC mimetics

iScience, 2023
Summary: Small molecule IAP antagonists - SMAC mimetics (SM) - are being developed as an anticancer therapy. SM therapy was demonstrated not only to sensitize tumor cells to TNFα-mediated cell death but also to exert immunostimulatory properties.
Catarina Pinto, Ksenija Slavic-Obradovic, Daniela Fürweger, Barbara Thaler, Abdallah Souabni, Sebastian Carotta, Martin Aichinger, Ulrich Reiser, Maria Antonietta Impagnatiello, Iñigo Tirapu   +9 more
doaj   +1 more source

Development of OX40 agonists for canine cancer immunotherapy

iScience, 2022
Summary: Recent breakthroughs in cancer immunotherapy have provided unprecedented clinical benefits to human cancer patients. Cancer is also one of the most common causes of death in pet dogs.
Damien Ruiz, Chloe Haynes, Jonathan Marable, Chetan Pundkar, Rebecca L. Nance, Deepa Bedi, Payal Agarwal, Amol S. Suryawanshi, Amarjit Mishra, Bruce F. Smith, Maninder Sandey   +10 more
doaj   +1 more source

Comparative assessment of genes driving cancer and somatic evolution in non-cancer tissues: an update of the Network of Cancer Genes (NCG) resource

Genome Biology, 2022
Background Genetic alterations of somatic cells can drive non-malignant clone formation and promote cancer initiation. However, the link between these processes remains unclear and hampers our understanding of tissue homeostasis and cancer development ...
Lisa Dressler, Michele Bortolomeazzi, Mohamed Reda Keddar, Hrvoje Misetic, Giulia Sartini, Amelia Acha-Sagredo, Lucia Montorsi, Neshika Wijewardhane, Dimitra Repana, Joel Nulsen, Jacki Goldman, Marc Pollitt, Patrick Davis, Amy Strange, Karen Ambrose, Francesca D. Ciccarelli   +15 more
doaj   +1 more source

Pioneer factors in development and cancer

iScience, 2021
Summary: Transcription factors (TFs) are essential mediators of epigenetic regulation and modifiers of penetrance. Studies from the past decades have revealed a sub-class of TF that is capable of remodeling closed chromatin states through targeting ...
Benjamin D. Sunkel, Benjamin Z. Stanton
doaj   +1 more source

Cellular and molecular effects of PNCK, a non-canonical kinase target in renal cell carcinoma

iScience, 2022
Summary: Renal cell carcinoma (RCC) is a fatal disease when advanced. While immunotherapy and tyrosine kinase inhibitor-based combinations are associated with improved survival, the majority of patients eventually succumb to the disease.
Derek J. Essegian, Valery Chavez, Floritza Bustamante, Stephan C. Schürer, Jaime R. Merchan   +4 more
doaj   +1 more source